ArticlePloS one2014

The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity.

Anne Kleijn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.